Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opzelura in seborrheic dermatitis
NCT05787860Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Nov 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruxolitinib cream in seborrheic dermatitis (SD), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Investigator Global Assessment of 0 or 1 at 4 weeks. Started Nov 2022; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on NCT05787860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05787860.